Article Text

Download PDFPDF
EV043/#204  Different surgical methods for stage IVB cervical cancer patients receiving chemotherapy: a population-based study
  1. Haoran Li,
  2. Jiao Wu and
  3. Xi Cheng
  1. Fudan University Shanghai Cancer Center, Shanghai, China

Abstract

Introduction To assess survival differences between non-extensive surgery (NES) and extensive surgery (ES) in initially diagnosed FIGO stage IVB cervical cancer patients receiving chemotherapy from a population-based database, the Surveillance, Epidemiology and End Results (SEER).

Methods FIGO stage IVB Cervical cancer patients receiving chemotherapy who underwent surgery between 2010-2019 were included. Propensity matching was conducted to minimize heterogeneity. The impact of survival was determined blog-rank test and Cox proportional hazards model.

Results 84 patients underwent NES while 70 underwent ES. After matching, patients receiving chemotherapy who underwent NES presented with a median overall survival (OS) of 51.5 months while patients who underwent ES had a median OS of 31 months. In all patients, no survival advantage was observed in ES group in contrast with NES group (P=0.066, hazard ratio [HR]=1.54, 95% confidence interval [CI]=10.97-2.42). Stratified analyses suggested extensive surgery associated with improved overall survival in patients with histology other than squamous cell carcinoma and adenocarcinoma (P=0.028, HR=0.36, 95%CI=0.15-0.89), AJCC T stage T1 (P=0.009, HR=0.18, 95%CI=0.05-0.66). Despite no survival benefit after remove of regional lymph node surgery (P=0.629, HR=0.88, 95%CI=0.53-1.47) in all patients, subgroup analyses demonstrated that patients younger than 50 (P=0.006, HR=0.21, 95% CI= 0.07-0.64), AJCC T stage T1 (P=0.002, HR=0.09, 95% CI=0.02-0.42), AJCC T stage T3 (P=0.001, HR=0.02, 95% CI=0.00-0.21) and hematogenous metastasis (P=0.036, HR=0.27, 95% CI=0.08-0.92) might achieve longer survival.

Conclusion/Implications In conclusion, ES or regional lymph node surgery may provide survival advantage for certain subgroup of FIGO IVB cervical cancer patients receiving chemotherapy. However, it deserves large scale prospective clinical trials to confirm.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.